Evidence map›Paper›PMID 41939466›Full record

ArticleFrontiers in oncology2026

Machine learning driven LD

Tanuj Sharma, Peter Sona, Jongsun Jung

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tanuj SharmaAI Drug Discovery and Development, Syntekabio, Inc., Daejeon, Republic of Korea.
Peter SonaAI Drug Discovery and Development, Syntekabio, Inc., Daejeon, Republic of Korea.
Jongsun JungAI Drug Discovery and Development, Syntekabio, Inc., Daejeon, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Accurate assessment of chemical toxicity is fundamental to cancer research, where early identification of hazardous compounds is critical for prioritizing carcinogenicity testing, therapeutic safety evaluation, and regulatory decision-making. Methods: We developed ChemModernBERT, a ModernBERT-based molecular language model pretrained using a curriculum learning strategy on more than 1.8 million SMILES strings to generate chemically informed sequence representations. Using a curated dataset of 8,898 compounds, we systematically compared four molecular representation learning approaches ChemBERT, ChemProp (a directed message passing neural network), ensemble learning, and ChemModernBERT for predicting median lethal dose (LD Results: ChemModernBERT achieved the lowest mean absolute error (MAE) on both internal (0.390) and external (0.393) evaluations and the highest coefficient of determination (R Discussion: These findings demonstrate that curriculum-pretrained transformer architectures provide a scalable and accurate framework for large-scale toxicity prediction. Such models can support computational pipelines for carcinogenicity assessment, dose selection, and early-stage chemical safety evaluation.

Indexed as

ChemModernBERTLD50 predictionLLMoral toxicitytoxicity prediction

Identifiers

PMID41939466
PMCPMC13043998

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.